Welcome to our blog community! This blog will show you how CED is helping emerging companies scale and grow in the Research Triangle Region. Plus we post news about our members and entrepreneurial resources.

Pages

Friday, January 25, 2013

Furiex Confirms Takeda's Receipt of FDA Approval of Three New Diabetes Therapies

CED Member Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited has received approval from the U.S. Food and Drug Administration of three new type 2 diabetes therapies, NESINA (alogliptin) and the fixed-dose combination therapies, OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl), for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

Under its agreement with Takeda, Furiex is entitled to receive a $25 million milestone payment as a result of this approval, as well as royalties on sales in the United States and potential sales-based milestones. Furiex has already been receiving royalty payments from Takeda for the sale of NESINA and LIOVEL in Japan.

"Receiving regulatory approvals for NESINA, OSENI and KAZANO in the U.S. marks an important milestone for Furiex," said Fred Eshelman, Pharm.D., chairman of Furiex. "These approvals should enable Takeda to build on the success of NESINA in Japan and leverage its more than 20 years of clinical and patient experience in the type 2 diabetes therapeutic area."

"We are pleased to see these important therapies become available for patients with type 2 diabetes," said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex. "Type 2 diabetes is a complex disease, requiring careful long-term disease management. We believe these new treatments in the U.S. offer patients additional therapeutic options for managing the disease."

RSS/Atom Feeds

WRAL Tech Wire

NC Biotech News

Testimonial

“For the last 10 years CED has helped me to know what I need to know and to meet the people I need to meet. Every company has a different path to success, but in North Carolina all of those paths go through CED. Every entrepreneur - aspiring or experienced - needs vision, perseverance, and CED.” ~Michael Pollack, co-founder Advanced Liquid Logic